These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7915537)

  • 21. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
    Ravdin PM; Valero V
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.
    Bruntsch U; Heinrich B; Kaye SB; de Mulder PH; van Oosterom A; Paridaens R; Vermorken JB; Wanders J; Franklin H; Bayssas M
    Eur J Cancer; 1994; 30A(8):1064-7. PubMed ID: 7654430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
    Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
    J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
    Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
    Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
    J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
    Einzig AI; Schuchter LM; Recio A; Coatsworth S; Rodriquez R; Wiernik PH
    Med Oncol; 1996 Jun; 13(2):111-7. PubMed ID: 9013474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
    Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
    J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
    Francis PA; Kris MG; Rigas JR; Grant SC; Miller VA
    Lung Cancer; 1995 Apr; 12 Suppl 1():S163-72. PubMed ID: 7551925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer.
    Latreille J; Cormier Y; Martins H; Goss G; Fisher B; Eisenhauer EA
    Invest New Drugs; 1996; 13(4):343-5. PubMed ID: 8824354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
    Gebbia V; Borsellino N; Testa A; Tirrito ML; Ferrera P; Colombo A; Mauceri G; Marrazzo A; Porretto F; Musso M
    Breast Cancer Res Treat; 2003 Jan; 77(2):99-108. PubMed ID: 12602908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
    van Hoesel QG; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom AT; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
    Ann Oncol; 1994 Jul; 5(6):539-42. PubMed ID: 7918126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
    Béhar A; Pujade-Lauraine E; Maurel A; Brun MD; Chauvin FF; Feuilhade de Chauvin F; Oulid-Aissa D; Hille D
    Br J Clin Pharmacol; 1997 Jun; 43(6):653-8. PubMed ID: 9205828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
    Piccart MJ; Gore M; Ten Bokkel Huinink W; Van Oosterom A; Verweij J; Wanders J; Franklin H; Bayssas M; Kaye S
    J Natl Cancer Inst; 1995 May; 87(9):676-81. PubMed ID: 7752272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
    Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
    J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.